These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 28667686)
1. Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer. Wang S; Chen J; Xie Z; Xia L; Luo W; Li J; Li Q; Yang Z J Clin Pharm Ther; 2017 Oct; 42(5):627-630. PubMed ID: 28667686 [TBL] [Abstract][Full Text] [Related]
2. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785 [TBL] [Abstract][Full Text] [Related]
3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538 [TBL] [Abstract][Full Text] [Related]
4. Optimal management of ALK-positive NSCLC progressing on crizotinib. Metro G; Tazza M; Matocci R; Chiari R; Crinò L Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695 [TBL] [Abstract][Full Text] [Related]
5. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status. Li DL; Chen XR; Ma SX; Chen LK Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783 [TBL] [Abstract][Full Text] [Related]
6. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949 [TBL] [Abstract][Full Text] [Related]
7. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Russo A; Franchina T; Ricciardi GR; Ferraro G; Scimone A; Bronte G; Russo A; Rolfo C; Adamo V Expert Rev Anticancer Ther; 2016 Jun; 16(6):615-23. PubMed ID: 27109446 [TBL] [Abstract][Full Text] [Related]
8. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026 [TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570 [TBL] [Abstract][Full Text] [Related]
10. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Toyokawa G; Seto T; Takenoyama M; Ichinose Y Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831 [TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer. Hong X; Chen Q; Ding L; Liang Y; Zhou N; Fang W; Chen X; Wu H Oncotarget; 2017 Jun; 8(25):41631-41640. PubMed ID: 28427213 [TBL] [Abstract][Full Text] [Related]
12. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer? Toyokawa G; Seto T Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564 [TBL] [Abstract][Full Text] [Related]
13. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436 [TBL] [Abstract][Full Text] [Related]
14. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Solomon BJ; Cappuzzo F; Felip E; Blackhall FH; Costa DB; Kim DW; Nakagawa K; Wu YL; Mekhail T; Paolini J; Tursi J; Usari T; Wilner KD; Selaru P; Mok TS J Clin Oncol; 2016 Aug; 34(24):2858-65. PubMed ID: 27022118 [TBL] [Abstract][Full Text] [Related]
15. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535 [TBL] [Abstract][Full Text] [Related]
16. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551 [TBL] [Abstract][Full Text] [Related]
17. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Rodig SJ; Shapiro GI Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129 [TBL] [Abstract][Full Text] [Related]